Troglitazone has no effect on red cell mass or other erythropoietic parameters

European Journal of Clinical Pharmacology

Volumn 55, Issue 2, 1999, Pages 101-104

  Young, M M R ^a   Squassante, L ^b   Wemer, J ^c   Van Marle, S P ^c   Dogterom, P ^c   Jonkman, J H G ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GSK   (Italy)

^c PRA International USA   (Netherlands)

Author keywords

Erythropoietic parameters; Plasma volume; Troglitazone

Indexed keywords

PLACEBO; SULFONYLUREA; TRANSCRIPTION FACTOR; TROGLITAZONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ERYTHROPOIESIS; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN ANALYSIS; HEMOLYSIS; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIA; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA VOLUME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TRANSFERRIN BLOOD LEVEL;

ADULT; CHROMANS; DOUBLE-BLIND METHOD; ERYTHROCYTE COUNT; ERYTHROCYTE INDICES; ERYTHROCYTE VOLUME; ERYTHROCYTES; ERYTHROPOIESIS; HEMATOCRIT; HEMOGLOBINS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RETICULOCYTES; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033005488     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050602     Document Type: Article

References (11)

1. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterisation of new oral antidiabetic agent CS-045 studies in KK and ob/ob mice and zucker fatty rats. Diabetes 37: 1549-1558
2. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H (1995) Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-bd/db mice. Metabolism 44: 486-490
3. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270: 12953-12956
4. Lenhard JM, Hamacher L, Paulik M, Beck K, Kliewer S, Lehmann J, Cobb J, Henke B, Wilson T, Parks D, Blanchard SG (1996) Analysis of thiazolidinedione, biguanide and retinoid effects on adipogenesis and the nuclear receptors PPARγ and RXR. Diabetologia 39 [Suppl 1]: A234 (Abstract 886)
5. Ciaraldi T, Huber-Knudsen K, Hickman M, et al (1995) Regulation of glucose transport in cultured muscle cells by novel hypoglycaemic agents. Metabolism 44: 976-982
6. Horikoshi H, Fujiwara T, Shimada M, et al (1990) Suppression of hepatic gluconeogenesis by CS-045 in KK mice and in perfused liver. Diabetes 39 [Suppl 1]: 111A (Abstract 442)
7. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM (1992) Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15: 193-203
8. Foot EA, Lettis S, Eckland DJA (1997) Evidence for troglitazone, a novel anti-diabetic agent, acting as an insulin action enhancer. Diabetologia 40 [Suppl 1]: A308 (Abstract 1209)
9. Kumar S, Boulton AJM, Beck-Nielsen H, et al for the troglitazone study group (1996) Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39: 701-709
10. Leutenegger M, Sacca L, Alderton C, Eckland D, Lettis S for the troglitazone study group (1997) Double-masked, placebo-controlled, dose-ranging study of troglitazone 10 to 200 mg once daily in non-insulin-dependent diabetes mellitus. Curr Ther Res 58: 403-416
11. Corrêa JCN, Hilsted J, Eckland D, Lettis S, Starkie M, Young M for the troglitazone study group (1997). Investigation of twice or three times daily dose regimen of troglitazone, an insulin action enhancer, in patients with non insulin dependent diabetes mellitus. Eur J Clin Res 9: 151-165